Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Phase I trials of targeted anticancer drugs: a need to refocus

Nature Reviews Drug Discovery volume 11, pages 889–890 (2012)Cite this article

Subjects

Abstract

As cancer therapy progresses through the development of molecularly targeted drugs, the focus of Phase I trials needs to shift towards investigating end points that could guide more effective trial design, dosing and choice of tumour setting for Phase II studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. American Society of Clinical Oncology. 2012 ASCO Annual Meeting Proceedings [online], (2012).

  2. Glassman, R. H. & Ratain, M. J. Biomarkers in early cancer drug development: limited utility. Clin. Pharmacol. Ther. 85, 134–135 (2009).

    Article  CAS  Google Scholar 

  3. Kummar, S. et al. Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies. Eur. J. Cancer 45, 741–746 (2009).

    Article  Google Scholar 

  4. Goodwin, R. et al. Targeted agents: how to select winners in preclinical and early clinical studies? Eur. J. Cancer 48, 170–178 (2012).

    Article  Google Scholar 

  5. Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in Phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708–720 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ernest C. Borden is at the Case Comprehensive Cancer Center, Taussig Cancer Institute R40, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.,

    Ernest C. Borden

  2. Afshin Dowlati is at the Case Comprehensive Cancer Center, University Hospitals, Euclid Avenue, Cleveland, Ohio 44106, USA.,

    Afshin Dowlati

Authors
  1. Ernest C. Borden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Afshin Dowlati
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernest C. Borden.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borden, E., Dowlati, A. Phase I trials of targeted anticancer drugs: a need to refocus. Nat Rev Drug Discov 11, 889–890 (2012). https://doi.org/10.1038/nrd3909

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3909

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer